Tenax Therapeutics (TENX) Stock Price, Quote & News

Latest News on TENX

Apr 16, 2025, 4:29 PM EDT - 10 days ago

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts

Mar 31, 2025, 8:00 AM EDT - 27 days ago

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 4:05 PM EDT - 4 weeks ago

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 5, 2025, 8:47 AM EST - 7 weeks ago

Tenax Therapeutics Announces $25 Million Private Placement

Mar 5, 2025, 8:42 AM EST - 7 weeks ago

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Mar 3, 2025, 8:00 AM EST - 7 weeks ago

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

Jan 31, 2025, 9:00 AM EST - 3 months ago

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Nov 15, 2024, 11:47 AM EST - 5 months ago

Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript)

Nov 13, 2024, 7:00 AM EST - 5 months ago

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Oct 31, 2024, 4:05 PM EDT - 6 months ago

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Aug 6, 2024, 7:13 AM EDT - 9 months ago

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

May 14, 2024, 8:00 AM EDT - 1 year ago

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Apr 30, 2024, 7:30 AM EDT - 1 year ago

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Apr 9, 2024, 8:30 AM EDT - 1 year ago

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

Mar 28, 2024, 8:30 AM EDT - 1 year ago

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Mar 12, 2024, 8:30 AM EDT - 1 year ago

Tenax Therapeutics to Present at the 36th Annual Roth Conference

Feb 29, 2024, 9:00 AM EST - 1 year ago

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Feb 20, 2024, 8:30 AM EST - 1 year ago

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Feb 8, 2024, 8:16 AM EST - 1 year ago

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

Feb 7, 2024, 8:01 PM EST - 1 year ago

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Feb 6, 2024, 10:01 AM EST - 1 year ago

Biotech stock Tenax Therapeutics more than doubled on Tuesday

Feb 6, 2024, 8:30 AM EST - 1 year ago

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Dec 29, 2023, 8:30 AM EST - 1 year ago

Tenax Therapeutics Announces Reverse Stock Split

Nov 17, 2023, 8:30 AM EST - 1 year ago

Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A.

Nov 13, 2023, 8:30 AM EST - 1 year ago

Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

Jul 19, 2023, 8:30 AM EDT - 1 year ago

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

May 31, 2023, 8:54 AM EDT - 2 years ago

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Apr 12, 2023, 8:45 AM EDT - 2 years ago

Tenax Therapeutics Provides 2023 Business Update

Mar 22, 2023, 8:45 AM EDT - 2 years ago

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Feb 3, 2023, 8:19 AM EST - 2 years ago

Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

Feb 1, 2023, 4:31 PM EST - 2 years ago

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Oct 10, 2022, 8:30 AM EDT - 2 years ago

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Sep 15, 2022, 8:30 AM EDT - 2 years ago

Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

May 23, 2022, 8:30 AM EDT - 3 years ago

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

May 18, 2022, 8:30 AM EDT - 3 years ago

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

Mar 31, 2022, 8:30 AM EDT - 3 years ago

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

Mar 30, 2022, 5:00 PM EDT - 3 years ago

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

Jan 31, 2022, 4:10 PM EST - 3 years ago

Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

Jan 12, 2022, 8:30 AM EST - 3 years ago

Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

Jan 4, 2022, 8:30 AM EST - 3 years ago

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

Nov 16, 2021, 8:30 AM EST - 3 years ago

Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update

Oct 6, 2021, 8:30 AM EDT - 3 years ago

Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)

Sep 9, 2021, 8:00 AM EDT - 3 years ago

Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Aug 17, 2021, 8:00 AM EDT - 4 years ago

Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update

Aug 12, 2021, 8:00 AM EDT - 4 years ago

Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Aug 5, 2021, 8:00 AM EDT - 4 years ago

Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Jul 7, 2021, 8:00 AM EDT - 4 years ago

Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

Jun 10, 2021, 8:30 AM EDT - 4 years ago

Tenax Therapeutics Set to Join Russell Microcap® Index

May 17, 2021, 5:15 PM EDT - 4 years ago

Market Cap	24.06M
Revenue (ttm)	0.00
Net Income (ttm)	-17.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	7,200
Avg Vol	29,990
Day's Range	N/A - N/A
Shares Out	4.15M
Stochastic %K	92%
Beta	1.88
Analysts	Strong Sell
Price Target	$22.00